SEC Comment Letter for BioPharmX Corp (CIK 0001504167) — Feb 25, 2020
BioPharmX Corp (CIK 0001504167)
Date: Feb. 25, 2020 · CIK: 0001504167 · Accession: 0000000000-20-001676
AI Filing Summary & Sentiment
File numbers found in text: 333-236526
Letter
February 24, 2020 Steven M. Bosacki Chief Executive Officer BioPharmX Corporation 900 E. Hamilton Ave., Suite 100 Campbell, California 95008 Re:BioPharmX Corporation Registration Statement on Form S-4 Filed February 20, 2020 File No. 333-236526 Dear Mr. Bosacki: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew E. Schwartz, Esq.
Show Raw Text
February 24, 2020
Steven M. Bosacki
Chief Executive Officer
BioPharmX Corporation
900 E. Hamilton Ave., Suite 100
Campbell, California 95008
Re:BioPharmX Corporation
Registration Statement on Form S-4
Filed February 20, 2020
File No. 333-236526
Dear Mr. Bosacki:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Andrew E. Schwartz, Esq.